Cargando…

Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways

Osteolytic bone disease is a condition of imbalanced bone homeostasis, characterized mainly by excessive bone-resorptive activity, which could predispose these populations, such as the old and postmenopausal women, to developing high risk of skeletal fragility and fracture. The nature of bone homeos...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kaiqiang, Zhu, Jian, Deng, Yi, Xu, Ximing, Kong, Fanqi, Sun, Xiaofei, Huan, Le, Ren, Changzhen, Sun, Jingchuan, Shi, Jiangang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104077/
https://www.ncbi.nlm.nih.gov/pubmed/33967763
http://dx.doi.org/10.3389/fphar.2021.629968
_version_ 1783689418584883200
author Sun, Kaiqiang
Zhu, Jian
Deng, Yi
Xu, Ximing
Kong, Fanqi
Sun, Xiaofei
Huan, Le
Ren, Changzhen
Sun, Jingchuan
Shi, Jiangang
author_facet Sun, Kaiqiang
Zhu, Jian
Deng, Yi
Xu, Ximing
Kong, Fanqi
Sun, Xiaofei
Huan, Le
Ren, Changzhen
Sun, Jingchuan
Shi, Jiangang
author_sort Sun, Kaiqiang
collection PubMed
description Osteolytic bone disease is a condition of imbalanced bone homeostasis, characterized mainly by excessive bone-resorptive activity, which could predispose these populations, such as the old and postmenopausal women, to developing high risk of skeletal fragility and fracture. The nature of bone homeostasis is the coordination between the osteoblasts (OBs) and osteoclasts (OCs). Abnormal activation of osteoclasts (OCs) could compromise the bone homeostasis, constantly followed by a clutch of osteolytic diseases, including postmenopausal osteoporosis, osteoarthritis, and rheumatoid arthritis. Thus, it is imperatively urgent to explore effective medical interventions for patients. The traditional Chinese medicine (TCM) gamabufotalin (CS-6) is a newly identified natural product from Chansu and has been utilized for oncologic therapies owing to its good clinical efficacy with less adverse events. Previous study suggested that CS-6 could be a novel anti-osteoporotic agent. Nevertheless, whether CS-6 suppresses RANK-(receptor activator of nuclear factor-κ B ligand)/TRAF6 (TNF receptor-associated factor 6)-mediated downstream signaling activation in OCs, as well as the effects of CS-6 on OC differentiation in vivo, remains elusive. Therefore, in this present study, we aimed to explore the biological effects of CS-6 on osteoclastogenesis and RANKL-induced activation of related signaling pathways, and further to examine the potential therapeutic application in estrogen-deficient bone loss in the mice model. The results of in vitro experiment showed that CS-6 can inhibit RANKL-induced OC formation and the ability of bone resorption in a dose-dependent manner at both the early and late stages of osteoclastogenesis. The gene expression of OC-related key genes such as tartrate-resistant acid phosphatase (TRAP), CTSK, DC-STAMP, MMP9, and β3 integrin was evidently reduced. In addition, CS-6 could mitigate the systemic estrogen-dependent bone loss and pro-inframammary cytokines in mice in vivo. The molecular mechanism analysis suggested that CS-6 can suppress RANKL/TRAF6-induced early activation of NF-κB and ERK/MAPK signaling pathways, which consequently suppressed the transcription activity of c-Fos and NFATc1. Taken together, this present study provided ample evidence that CS-6 has the promise to become a therapeutic candidate in treating osteolytic conditions mediated by elevated OC formation and bone resorption.
format Online
Article
Text
id pubmed-8104077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81040772021-05-08 Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways Sun, Kaiqiang Zhu, Jian Deng, Yi Xu, Ximing Kong, Fanqi Sun, Xiaofei Huan, Le Ren, Changzhen Sun, Jingchuan Shi, Jiangang Front Pharmacol Pharmacology Osteolytic bone disease is a condition of imbalanced bone homeostasis, characterized mainly by excessive bone-resorptive activity, which could predispose these populations, such as the old and postmenopausal women, to developing high risk of skeletal fragility and fracture. The nature of bone homeostasis is the coordination between the osteoblasts (OBs) and osteoclasts (OCs). Abnormal activation of osteoclasts (OCs) could compromise the bone homeostasis, constantly followed by a clutch of osteolytic diseases, including postmenopausal osteoporosis, osteoarthritis, and rheumatoid arthritis. Thus, it is imperatively urgent to explore effective medical interventions for patients. The traditional Chinese medicine (TCM) gamabufotalin (CS-6) is a newly identified natural product from Chansu and has been utilized for oncologic therapies owing to its good clinical efficacy with less adverse events. Previous study suggested that CS-6 could be a novel anti-osteoporotic agent. Nevertheless, whether CS-6 suppresses RANK-(receptor activator of nuclear factor-κ B ligand)/TRAF6 (TNF receptor-associated factor 6)-mediated downstream signaling activation in OCs, as well as the effects of CS-6 on OC differentiation in vivo, remains elusive. Therefore, in this present study, we aimed to explore the biological effects of CS-6 on osteoclastogenesis and RANKL-induced activation of related signaling pathways, and further to examine the potential therapeutic application in estrogen-deficient bone loss in the mice model. The results of in vitro experiment showed that CS-6 can inhibit RANKL-induced OC formation and the ability of bone resorption in a dose-dependent manner at both the early and late stages of osteoclastogenesis. The gene expression of OC-related key genes such as tartrate-resistant acid phosphatase (TRAP), CTSK, DC-STAMP, MMP9, and β3 integrin was evidently reduced. In addition, CS-6 could mitigate the systemic estrogen-dependent bone loss and pro-inframammary cytokines in mice in vivo. The molecular mechanism analysis suggested that CS-6 can suppress RANKL/TRAF6-induced early activation of NF-κB and ERK/MAPK signaling pathways, which consequently suppressed the transcription activity of c-Fos and NFATc1. Taken together, this present study provided ample evidence that CS-6 has the promise to become a therapeutic candidate in treating osteolytic conditions mediated by elevated OC formation and bone resorption. Frontiers Media S.A. 2021-04-23 /pmc/articles/PMC8104077/ /pubmed/33967763 http://dx.doi.org/10.3389/fphar.2021.629968 Text en Copyright © 2021 Sun, Zhu, Deng, Xu, Kong, Sun, Huan, Ren, Sun and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sun, Kaiqiang
Zhu, Jian
Deng, Yi
Xu, Ximing
Kong, Fanqi
Sun, Xiaofei
Huan, Le
Ren, Changzhen
Sun, Jingchuan
Shi, Jiangang
Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways
title Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways
title_full Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways
title_fullStr Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways
title_full_unstemmed Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways
title_short Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways
title_sort gamabufotalin inhibits osteoclastgenesis and counteracts estrogen-deficient bone loss in mice by suppressing rankl-induced nf-κb and erk/mapk pathways
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104077/
https://www.ncbi.nlm.nih.gov/pubmed/33967763
http://dx.doi.org/10.3389/fphar.2021.629968
work_keys_str_mv AT sunkaiqiang gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT zhujian gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT dengyi gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT xuximing gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT kongfanqi gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT sunxiaofei gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT huanle gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT renchangzhen gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT sunjingchuan gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways
AT shijiangang gamabufotalininhibitsosteoclastgenesisandcounteractsestrogendeficientbonelossinmicebysuppressingranklinducednfkbanderkmapkpathways